Skip to main content
Top
Published in: PharmacoEconomics - Open 4/2019

Open Access 01-12-2019 | Original Research Article

The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta

Authors: Ilke Akpinar, Arto Ohinmaa, Lars Thording, Dat T. Tran, Richard N. Fedorak, Lawrence Richer, Philip Jacobs

Published in: PharmacoEconomics - Open | Issue 4/2019

Login to get access

Abstract

Objective

Our objective was to describe the costs of industry-sponsored clinical trials for medical devices in Northern Alberta, Canada.

Methods

We used centralized data to identify all industry-sponsored medical device clinical trials initiated in Northern Alberta from 2012 to 2016. For each arm of each trial, we calculated the price of devices provided by the sponsor and the cost of clinical and administrative services that were incurred to clinically operationalize the treatment.

Results

Our sample consisted of 18 device trials initiated between January 2012 and January 2016. The overall cost (Canadian dollars [$Can], year 2018 values) per enrolee was $Can18,243 for the experimental arm and $Can13,827 for the control arm. Devices were the highest cost component, at $Can13,446 per enrollee in the experimental arm. Clinical costs in the control arms were higher on average ($Can7202 vs. 2504) than those in the experimental arms.

Conclusion

Data from industry-sponsored clinical trials can provide important information on the full costs of device-related interventions. As device costs rise, and as policy makers require more evidence on device-related treatments, the cost of medical device-driven interventions should be documented along with their effectiveness.
Literature
1.
go back to reference Husereau D, Arshoff L, Bhimani S, N. A. Medical device and diagnostic pricing and reimbursement in Canada. Institute of Health Economics 2015. Report No.: 978-1-926929-63-7 Contract No.: 23 May 2018. Husereau D, Arshoff L, Bhimani S, N. A. Medical device and diagnostic pricing and reimbursement in Canada. Institute of Health Economics 2015. Report No.: 978-1-926929-63-7 Contract No.: 23 May 2018.
5.
go back to reference Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, et al. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation. 2010;122(24):2545–50.CrossRef Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, et al. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation. 2010;122(24):2545–50.CrossRef
6.
go back to reference Redekop WKMJ, Verboom P, Lovas K, Kalo Z, Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics. 2003;21(16):1171–83.CrossRef Redekop WKMJ, Verboom P, Lovas K, Kalo Z, Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics. 2003;21(16):1171–83.CrossRef
16.
go back to reference Tran DT, Akpinar I, Fedorak R, Jonsson E, Mackey J, Richer L, et al. The economic contribution of industry-sponsored pharmaceutical clinical trials. J Pharm Pharm Sci. 2017;20(1):407–14.CrossRef Tran DT, Akpinar I, Fedorak R, Jonsson E, Mackey J, Richer L, et al. The economic contribution of industry-sponsored pharmaceutical clinical trials. J Pharm Pharm Sci. 2017;20(1):407–14.CrossRef
17.
go back to reference Akpinar I, Jacobs P, Tran TD. Forecasting pharmaceutical prices for economic evaluations when there is no market: a review. Pharmacoecon Open. 2017;1(1):65–8.CrossRef Akpinar I, Jacobs P, Tran TD. Forecasting pharmaceutical prices for economic evaluations when there is no market: a review. Pharmacoecon Open. 2017;1(1):65–8.CrossRef
19.
go back to reference Grimm SE, Stevens JW. When future change matters: modeling future price and diffusion in health technology assessments of medical devices. Value Health. 2016;19(6):720–6.CrossRef Grimm SE, Stevens JW. When future change matters: modeling future price and diffusion in health technology assessments of medical devices. Value Health. 2016;19(6):720–6.CrossRef
21.
go back to reference Mealing S, Woods B, Hawkins N, Cowie MR, Plummer CJ, Abraham WT, et al. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. Heart. 2016;102(21):1742–9.CrossRef Mealing S, Woods B, Hawkins N, Cowie MR, Plummer CJ, Abraham WT, et al. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. Heart. 2016;102(21):1742–9.CrossRef
22.
go back to reference Gatlin SW, Kim DW, Mahle WT. Cost analysis of percutaneous pulmonary valve replacement. Am J Cardiol. 2011;108(4):572–4.CrossRef Gatlin SW, Kim DW, Mahle WT. Cost analysis of percutaneous pulmonary valve replacement. Am J Cardiol. 2011;108(4):572–4.CrossRef
24.
go back to reference Gladwell DHT, Cook M, Akehurst R. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK. Appl Health Econ Health Policy. 2014;12(6):611–22.CrossRef Gladwell DHT, Cook M, Akehurst R. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK. Appl Health Econ Health Policy. 2014;12(6):611–22.CrossRef
25.
go back to reference Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60(14):1271–7.CrossRef Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60(14):1271–7.CrossRef
29.
go back to reference Wenzl M, Mossialos E. Prices for cardiac implant devices may be up to six times higher in the US than in some European countries. Health Aff (Millwood). 2018;37(10):1570–7.CrossRef Wenzl M, Mossialos E. Prices for cardiac implant devices may be up to six times higher in the US than in some European countries. Health Aff (Millwood). 2018;37(10):1570–7.CrossRef
Metadata
Title
The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta
Authors
Ilke Akpinar
Arto Ohinmaa
Lars Thording
Dat T. Tran
Richard N. Fedorak
Lawrence Richer
Philip Jacobs
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
PharmacoEconomics - Open / Issue 4/2019
Print ISSN: 2509-4262
Electronic ISSN: 2509-4254
DOI
https://doi.org/10.1007/s41669-019-0137-0

Other articles of this Issue 4/2019

PharmacoEconomics - Open 4/2019 Go to the issue